Guideline / position statementindependent cross-checkfull text checked★ key study I-INS-132 in-depth review
US diabetes standards 2026: what type 1 diabetes is
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026.
Overview
American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358893 · DOI 10.2337/dc26-S002
Type 1 diabetes is an autoimmune destruction of insulin-producing cells that leads to absolute insulin deficiency.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Define diabetes types.
- How was the study done?
Guideline.
- How many people, animals or samples were studied?
Not applicable.
- What was actually found?
T1D = autoimmune, insulin-deficient; 5-10% of diabetes.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
Type 1 diabetes is real and needs insulin.
- What are the study's limitations?
Guideline.
- What does it say about Elawady's specific claim?
Contradicts C-INS-07.
- Do the results apply to Germany and Europe?
Identical European definitions.
- What can explicitly not be concluded from this study?
Not applicable.
Scientific in-depth review
1. Full reference
- Authors
- American Diabetes Association Professional Practice Committee for Diabetes
- Journal
- Diabetes Care
- Year
- 2026
- Identifier
- PMID 41358893 DOI 10.2337/dc26-S002
- Verification
- verified – PubMed efetch 2026-10-26; Crossref 2026-10-26; full text read at the PMC URL
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
ADA.
2. Research question
How is diabetes classified?
3. Study design and population
- Study design
- Guideline / position statement – Clinical practice guideline (ADA Standards of Care, section 2)
- Population
People with diabetes
- Country
USA (international use)
- Period
2026
- Sample size
Not applicable
- Inclusion and exclusion criteria
Not applicable
4. Methods and endpoints
- Exposure / intervention
Not applicable
- Comparator
Not applicable
- Endpoints
Classification
- Statistical methods
Not applicable
5. Actual results
- Results
Type 1 diabetes is 'due to autoimmune beta-cell destruction, usually leading to absolute insulin deficiency'; it accounts for 5-10% of diabetes. Adults with slowly progressive autoimmune diabetes 'eventually become insulin dependent and are at risk for DKA'. Partial remission ('honeymoon') is commonly seen after diagnosis of T1D.
- Absolute risks
not applicable
- Authors' conclusion
T1D is autoimmune insulin deficiency.
6. Strengths
- Current, evidence-graded recommendations
7. Weaknesses
- Consensus elements; partly expert opinion
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Guideline; graded recommendations from systematic evidence review.
9. Assessment of the statistical interpretation
Not applicable
10. Relevance to the specific claim
Defines T1D as autoimmune absolute insulin deficiency, contradicting 'there is no type 1' and 'type 1 is athletes' high demand'. Acknowledges a transient partial remission phase (which can be misread as cure).
11. Independent contrary findings
12. Transferability to Germany and Europe
Directly applicable; same biology and clinical standards in Europe.
13. Overall methodological judgement
Authoritative classification.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |